CrushSCI.com
Journal Selection & Manuscript Polishing Services
Journal of Thoracic Oncology journal cover Medicine
Back to journal directory

Review Cycle Records

Journal of Thoracic Oncology

Elsevier SCIE Non-OA
2026 Emerging Zone 12025 CAS Zone 1 TOP2025 JCR Q1
98Average days
89Median days
12Fastest days
245Longest days
2,6642025 publications

Paper Review Records

All Paper Review Records

10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

43 days

First-Line Integration of Local Ablative Therapy With EGFR Tyrosine Kinase Inhibitors in Advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis

AuthorsLeonardo Brunetti; Giacomo Colella; Giuseppina Rita Di Fazio; Giulia La Cava; Valentina Santo; Federica Pecci; Julia K. Rotow; Jessica R. Bauman; Amin H. Nassar; Elio Adib; Abdul Rafeh Naqash; Marco Tagliamento; Roberto Ferrara; Fabrizio Citarella; Marco Russano; Biagio Ricciuti; Corinne Faivre-Finn; Lizza E.L. Hendriks; Antonio Passaro; Bruno Vincenzi; Fabian Acker; Lisa Derosa; David Planchard; Hugo J.W.L. Aerts; Silvia Novello; Francesco Passiglia; Carlo Greco; Sara Ramella; Alessio Cortellini

AffiliationsDepartment of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy; Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; GROW Research Institute for Cancer and Reproduction, Maastricht University, Maastricht, The Netherlands; Department of Surgery and Cancer, Imperial College of London, London, United Kingdom; Medical Oncology, ASST Fatebenefratelli-Sacco, Milano, Italy; Department of Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Section of Medical Oncology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut; Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts; Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, Oklahoma; Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy; IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom The Christie NHS Foundation Trust, Manchester, United Kingdom; Department of Pulmonary Diseases, GROW—Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy; Department of Medicine II, Hematology and Oncology, University Hospital, Goethe University Frankfurt, Frankfurt, Germany; Tumor Immunology and Cancer Immunotherapy, Université Paris-Saclay, Gustave Roussy, Inserm UMR1015, Villejuif, France; Department of Medical Oncology, Gustave Roussy, Villejuif, France; Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France Faculty of Medicine, Paris-Saclay University, Paris, France; Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Harvard Institutes of Medicine, Boston, Massachusetts; Radiology and Nuclear Medicine, CARIM and GROW, Maastricht University, Maastricht, The Netherlands; Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Turin, Italy; Operative Research Unit of Radiation Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy

Source PDF DOI Publisher page
171 days

YAP1 Defines an Emergent, Plastic Population of Relapsed SCLC

AuthorsC. Allison Stewart; Kavya Ramkumar; Runsheng Wang; Yuanxin Xi; Alexa Halliday; Lixia Diao; Qi Wang; Alejandra Serrano; Sarah Groves; Simon Heeke; Azusa Tanimoto; Laura Kaiser; Whitney Lewis; Mukulika Bose; Pedro Rocha; Loukia Karacosta; Vito Quaranta; Jing Wang; Julie George; Luisa Maren Solis Soto; Bingnan Zhang; John V. Heymach; Lauren A. Byers; Carl M. Gay

AffiliationsDepartment of Thoracic/Head & Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia; Department of Translational Genomics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Medical Oncology, Thoracic Tumors Unit, Vall d’Hebron University Hospital, Barcelona, Spain; Institute for Experiential AI, Northeastern University, Boston, Massachusetts; Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine and University Hospital Cologne, University Hospital of Cologne, Cologne, Germany

Source PDF DOI Publisher page
109 days

Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial

AuthorsSuresh Senan; Byoung Chul Cho; Konstantin K. Laktionov; Yoshitaka Zenke; Ki Hyeong Lee; Qiming Wang; Alejandro Navarro; Eva Lotte Buchmeier; Sema Sezgin Goksu; Andrzej Badzio; Anhui Shi; Davey B. Daniel; Milada Zemanova; Puneeth Iyengar; Luis Paz-Ares; Leah Szadkowski; Priti Chugh; W. Victoria Lai; David R. Spigel

AffiliationsAmsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Federal State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russia; National Cancer Center Hospital East, Kashiwa, Japan; Chungbuk National University Hospital, Cheongju, Republic of Korea; The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, People's Republic of China; Hospital Vall d'Hebron and Vall d’Hebron Institute of Oncology, Barcelona, Spain; Hospitals of the City of Cologne gGmbH, Cologne, Germany; Akdeniz University Medical Faculty, Antalya, Türkiye; Medical University of Gdansk, Gdansk, Poland; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China; Tennessee Oncology PLLC, Nashville, Tennessee; First Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic; Memorial Sloan Kettering Cancer Center, New York, New York; Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, Spain; AstraZeneca, Mississauga, Ontario, Canada; AstraZeneca, Waltham, Massachusetts; AstraZeneca, New York, New York; Sarah Cannon Research Institute, Nashville, Tennessee

Source PDF DOI Publisher page
62 days

Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research Group

AuthorsAaron C. Tan; Bin-Chi Liao; Molly Li; David Lee; Yuji Uehara; Lucksamon Thamlikitkul; Jia-Tao Zhang; Meimei Zheng; Chee Khoon Lee; Nick Pavlakis; Thomas John; Ross A. Soo; Anders Skanderup; Pei Jye Voon; Beung-Chul Ahn; Sehhoon Park; Hidetoshi Hayashi; Yasushi Goto; Hidehito Horinouchi; Yasushi Yatabe; Thanyanan Reungwetwattana; James Chih-Hsin Yang; Dong-Wan Kim; Tony Mok; Daniel S.W. Tan; Yi-Long Wu; Myung-Ju Ahn

AffiliationsDivision of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China; Sunway Medical Centre, Kuala Lumpur, Malaysia; Department of Thoracic Oncology, National Cancer Centre Hospital, Chuo-ku, Tokyo, Japan; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People's Republic of China; NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore; Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore; Department of Radiotherapy, Oncology and Palliative Care, Hospital Umum Sarawak, Kuching, Sarawak, Malaysia; Center for Lung Cancer, Division of Hematology and Oncology, Department of Internal Medicine, Research Institute and Hospital, National Cancer Center, Gyeonggi-do, Republic of Korea; Department of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan; Department of Diagnostic Pathology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Internal Medicine, Seoul National University Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea

Source PDF DOI Publisher page
110 days

Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial

AuthorsBenjamin Levy; Luis Paz-Ares; Chien-Chung Lin; Scott Herbert; Tsung-Ying Yang; Anthony Tolcher; Yanyan Lou; Yoshitaka Zenke; Diego Cortinovis; Enriqueta Felip; Manuel Domine; Konstantinos Leventakos; Emiliano Calvo; Atsushi Horiike; Edward Pan; Priyanka Basak; Daisy Lin; Wen Gu; Rachel Chiaverelli; Michael J. Chisamore; Yasushi Goto

AffiliationsThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Baltimore, Maryland; Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense & CiberOnc, Madrid, Spain; Department of Internal Medicine, National Cheng Kung University Hospital and Tainan Hospital, Ministry of Health and Welfare, Tainan City, Taiwan; Quantum, Santa Fe, New Mexico; Department of Chest Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; NEXT Oncology, San Antonio, Texas; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy; Medicine and Surgery Department, University of Milano-Bicocca, Milano, Italy; Vall d’Hebron Hospital Campus, Vall d’Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Spain; Department of Oncology, Hospital Universitario Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain; Department of Oncology, Mayo Clinic, Rochester, Minnesota; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan;; Daiichi Sankyo, Inc., Basking Ridge, New Jersey; Oncology Early Development – External Collaborations, Merck & Co., Inc., Rahway, New Jersey; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan

Source PDF DOI Publisher page
50 days

First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial

AuthorsYun Fan; Yanqiu Zhao; Dingzhi Huang; Jun Zhao; Tai Qin; Wanyu He; Chenqi Chen; Pu Sun; Kirsha Naicker; Yong Song

AffiliationsDepartment of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, China; Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China; Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department I of Thoracic Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China; Clinical Development–Solid Tumors, BeOne Medicines, Ltd., Beijing, China; Statistics, BeOne Medicines, Ltd., New York, New York; Clinical Biomarkers, BeOne Medicines, Ltd., Beijing, China; Clinical Development–Solid Tumors, BeOne Medicines, Ltd., London, United Kingdom; Department of Respiratory and Critical Care Medicine, Jinling Hospital, Nanjing Medical University, Nanjing, China

Source PDF DOI Publisher page
245 days

Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC

AuthorsSantiago Ponce; Miguel Ruiz-Torres; Alejandro Falcón; Gregory M. Cote; Reyes Bernabé; Jessica J. Lin; Juan Manuel Coya; Marta Jiménez-Muñoz; Pablo Fernández-Puyuelo; Amparo Sánchez; Jon Zugazagoitia; Alvaro Ucero; Javier Baena; Helena Bote de Cabo; Mercedes Herrera; Javier Torres-Jiménez; Maria Zurera; Carmen Kahatt; Jose Antonio Lopez-Vilariño; Sara Martinez; Mariano Siguero; Marcos Malumbres; Irene Ferrer; Luis Paz-Ares

AffiliationsDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; Centro Nacional de Investigaciones Oncológicas (CNIO)-Hospital 12 de Octubre (H12O) Lung Cancer Clinical Cancer Research Unit, Instituto de Investigación Biomédica i+12 and CNIO, Madrid, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain; Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain; Massachusetts General Hospital, Boston, Massachusetts; Physiology and Medicine Departments, Universidad Complutense, Madrid, Spain; Oncology Clinical Development, Pharma Mar, Colmenar Viejo, Madrid, Spain; Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

Source PDF DOI Publisher page
99 days

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort

AuthorsOliver Illini; Anna-Carina Hund; Hans-Georg Kopp; Mor Moskovitz; Giannis Mountzios; Wolfgang M. Brueckl; Martin Früh; Marie-Elisabeth Leßmann; Petros Christopoulos; Albrecht Stenzinger; Michael Thomas; Roni Gillis; Nir Peled; Fabian Acker; Alfredo Addeo; Andriani Charpidou; Christian Grohé; Horst-Dieter Hummel; Laetitia Mauti; Sacha I. Rothschild; Sabine Schmid; Christian Schumann; Damien Urban; Robert Wurm; Simon Ekman; Marcus Skribek; Franziska Glanemann; Marcel Wiesweg; Christoph Jakob Ackermann; Sofia Agelaki; Petra Hoffknecht; Marko Jakopović; Jens Kern; David König; Katharina Kostenzer; Cornelia Kropf-Sanchen; Eckart Laack; David Lang; Laurenz Nagl; Georg Pall; Martin Reck; Waleed Kian; Anna T. Allemann; Jürgen Alt; David Araújo; Hanibal Bohnenberger; Alexandros Bokas; Hannah Fabikan; Krainer-Jacobs Julie; Christoph Weinlinger; Adrianus Johannes de Langen; Evangelos Georgios Fergadis; Rieke Fischer; Elena Fountzilas; Patrizia Froesch; Nikolaj Frost; Frank Griesinger; Franziska Jordan; Charisios Karanikiotis; Barbara Kiesewetter; Ippokratis Korantzis; Andrea Lopes Machado; Panagiota Economopoulou; Arnold Pilz; Patrick Reimann; Achim Rittmeyer; Akram Saad; Konstantinos Samitas; Karsten Schulmann; Riyaz Shah; Jan Alexander Stratmann; Hossein Taghizadeh; Kai Tammoscheit; Amanda Tufman; Jan-Phillip Weber; Ewald Wöll; Arschang Valipour; Tobias R. Overbeck; Maximilian J. Hochmair

AffiliationsDepartment of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria; Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, Austria; Department of Hematology and Medical Oncology, University Medical Center Goettingen, Goettingen, Germany; National Network Genomic Medicine, Cologne, Germany; Department of Hematology, Oncology, and Palliative Care, Robert Bosch Center for Tumor Diseases, Stuttgart, Germany; Davidoff Cancer Center, Beilinson MC, Petah Tikva, Israel; 4th Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece; Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nuernberg, Nuremberg, Germany; Department of Oncology and Hematology, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland; Department of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland; Department of Medicine I, University Hospital Carl Gustav Carus Dresden, TU Dresden, Dresden, Germany; Institute for Pathology, University Hospital Carl Gustav Carus Dresden, TU Dresden, Dresden, Germany; Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Germany; Department of Translational Pulmonology, Heidelberg University Hospital, Heidelberg, Germany; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem, Israel; Goethe University Frankfurt, University Hospital, Department of Medicine 2, Hematology and Oncology, Frankfurt, Germany; Oncology Department, University Hospital Geneva, Geneva, Switzerland; Oncology Unit, 3rd Department of Internal Medicine and Laboratory Medical School, National and Kapodistrian University of Athens, Sotiria General Hospital, Athens, Greece; Klinik für Pneumologie, Evangelische Lungenklinik, Berlin, Germany; Translational Oncology/Early Clinical Trial Unit (ECTU), Bavarian Cancer Research Center, National Center for Tumor Diseases, Comprehensive Cancer Center Mainfranken and University Hospital Würzburg, Würzburg, Germany; Medizinische Onkologie, Kantonsspital Winterthur, Winterthur, Switzerland; Department of Internal Medicine, Center of Oncology & Hematology, Cantonal Hospital Baden, Baden, Switzerland and University of Basel, Medical Faculty, Basel, Switzerland; Respiratory Critical Care, Allgäu Clinics, Kempten and Immenstadt, Kempten, Germany; Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria; Department of Thoracic Oncology, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Department of Oncology and Haematologie Thun-Spiez-Berner-Oberland, Thun, Switzerland; Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece; Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece; Department of Thoracic Oncology, Niels-Stensen-Kliniken, Franziskus-Hospital Harderberg, Georgsmarienhütte, Germany; Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia; KWM-Standort Missioklinik, Würzburg, Germany; Division of Medical Oncology, University Hospital Basel, Basel, Switzerland; Department of Pneumology, LKH Hochzirl-Natters, Tirol Kliniken, Natters, Austria; Department II for Internal Medicine, University Hospital of Ulm, Ulm, Germany; Hemato-Oncology Hamburg, Hamburg, Germany; Department of Internal Medicine 4 - Pneumology, Kepler University Hospital, Johannes Kepler University Linz, Linz, Austria; Department of Internal Medicine V - Haematology and Oncology, Tirol Kliniken, Medical University Innsbruck, Innsbruck, Austria; Department of Internal Medicine 2, Kardinal Schwarzenberg Hospital, Schwarzach im Pongau, Austria; Department of Thoracic Oncology, LungenClinic, Grosshansdorf, Germany; Airway Research Center North, German Center for Lung Research, Giessen, Germany; Oncology Department, Samson Assuta Ashdod University Hospital, Ashdod, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Department of Medical Oncology, Tumorzentrum, Luzerner Kantonsspital, Spitalstrasse, Luzern, Switzerland; Department of Hematology and Medical Oncology, University Medical Center Mainz, Mainz, Germany; Department of Pulmonology, Unidade Local de Saúde São João, Porto, Portugal; Faculty of Medicine, Universidade do Porto, Porto, Portugal; Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany; 1st Department of Clinical Oncology, Theagenio Cancer Hospital of Thessaloniki, Thessaloniki, Greece; Department of Thoracic Oncology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Amsterdam, The Netherlands; Medical Oncology Department, Metaxa Cancer Hospital, Piraeus, Greece; Department I of Internal Medicine, Center for Integrated Oncology (CIO), University Hospital of Cologne, Cologne, Germany; European University Cyprus, German Oncology Center, Nicosia, Cyprus; Department of Medical Oncology, St Luke's Clinic, Thessaloniki, Greece; Istituto Oncologico della Svizzera Italiana (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland; Department of Infectious Diseases and Pulmonary Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt Universität Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Hematology and Medical Oncology, Pius-Hospital, Department of Internal Medicine-Oncology, University Medicine Oldenburg, Oldenburg, Germany; Department of Pneumology, University Hospital Salzburg, Salzburg, Austria; Department of Medical Oncology, Euromedica - Kianous Stavros Clinic, Thessaloniki, Greece; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria; St Luke’s Hospital, Panorama, Thessaloniki, Greece; Department of Pulmonary Oncology - ULS Santa Maria/Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; Oncology Unit, Second Department of Internal Medicine, Attikon University Hospital, Athens, Greece; Department of Respiratory and Pulmonary Diseases, Clinic Penzing, Vienna Healthcare Group, Vienna, Austria; Ludwig Boltzmann Institute for Lung Health, Vienna, Austria; Department of Haematology, Oncology, Gastroenterology and Infectiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Department of Thoracic Oncology, LKI Lungenfachklinik Immenhausen, Immenhausen, Germany; Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Israel; 7th Respiratory Department, Athens Chest Hospital “Sotiria,” Athens, Greece; Department of Pneumology, Division of Thoracic Oncology and Palliative Care, Lungenklinik Hemer, Hemer, Germany; GenesisCare Maidstone, Kings Hill, West Malling, United Kingdom; UKS Homburg, Homburg, Germany; Oncology, University Hospital St. Pölten, St. Pölten, Lower Austria, Austria; Karl Landsteiner Institute of Nephrology and Hematooncology, Lower Austria, Austria; Hessenklinik Stadtkrankenhaus Korbach, Korbach, Germany; Department of Internal Medicine V, Comprehensive Pneumology Center (CPC-M), Ludwig-Maximilians-Universität Munich, Germany; German Center for Lung Research (DZL), Bavarian Center for Cancer Research (BZKF), Germany; MVZ Oncology and Hematology, Sachsenring, Köln, Germany; Head of Department of Internal Medicine, Head of Laboratory Unit, Executive Medical Director, Krankenhaus St. Vinzenz, Zams, Austria

Source PDF DOI Publisher page
12 days

Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay

AuthorsJamie Feng; Sameena Khan; Thomas K. Waddell; Kazuhiro Yasufuku; Zachary Coyne; Deirdre Kelly; Nicholas Meti; Najib Safieddine; Michael Ko; Andrew Pierre; Shaf Keshavjee; Elliot Wakeam; Laura Donahoe; Marcelo Cypel; Jonathan Yeung; Marc de Perrot; Negar Ahmadi; Sayf Gazala; Carmine Simone; David Parente; Mary R. Rabey; Jennifer H. Law; Janice J.N. Li; Alexandra Salvarrey; Lisa W. Le; Andrew Seto; Michael Cabanero; Ming-Sound Tsao; Christodoulos Pipinikas; Amber Chevalier; Scott V. Bratman; Natasha B. Leighl

AffiliationsDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Division of Thoracic Surgery, University Health Network (UHN), Toronto, Ontario, Canada; Division of Thoracic Surgery, Michael Garron Hospital, Toronto, Ontario, Canada; Division of Thoracic Surgery, Unity Health Toronto, Toronto, Ontario, Canada; Department of Biostatistics, University Health Network, Toronto, Ontario, Canada; Division of Pathology and Cytogenetics, Laboratory Medicine Program, UHN, Toronto, Ontario, Canada; NeoGenomics Inc., Fort Myers, Florida; Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Source PDF DOI Publisher page
79 days

Clinical Value of Combining Molecular and Immune Blood Tests to Safely Reduce False Positives in Low-Dose Computed Tomography Lung Cancer Screening

AuthorsAnna Zanghì; Massimo Moro; Orazio Fortunato; Miriam Segale; Federica Sabia; Paola Suatoni; Roberta E. Ledda; Luigi Rolli; Alfonso Marchianò; Ugo Pastorino; Gabriella Sozzi; Mattia Boeri

AffiliationsUnit of Epigenomics & Biomarkers of Solid Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Unit of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Section of Radiology, Unit of Surgical Sciences, Department of Medicine and Surgery (DiMeC), University of Parma, Parma, Italy; Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review96.4 days

Median77 days

Contact CrushSCI

Contact CrushSCI

Leave your contact details so we can discuss your manuscript, editing needs, and submission plan.

Selected service: Paper Editing Service

Or leave your contact details

WhatsApp, Telegram, WeChat, and email are all optional, but at least one is required. Once received, we will contact you as soon as possible.